COSTA MESA, Calif., May 5 /PRNewswire-FirstCall/ -- CNS Response, Inc. (OTC Bulletin Board: CNSO) announced today that it has appointed William E. Bunney, Jr., MD to its Scientific Advisory Board. Dr. Bunney is Senior Associate Dean for Research and Distinguished Professor, Department of Psychiatry and Human Behavior, School of Medicine, University of California, Irvine.
Len Brandt, Chairman and CEO of CNS Response, reported, "Considering Dr. Bunney's distinguished career and his position as a thought leader in psychiatry, we are honored that he has accepted a position on our Scientific Advisory Board. His informal counsel has been very valuable to CNS Response during the past year. I am certain that Dr. Bunney's continued input will benefit CNS Response's mission to provide physiological guidance to treatment."
In addition to his position at the University of California, Irvine, Dr. Bunney has held key appointments with several prominent government institutions and research organizations focused on mental health and behavioral sciences-related issues. Among his affiliations, Dr. Bunney currently serves on the Scientific Advisory Boards of the Harvard International Brain Repository and the World Health Organization (WHO) Expert Panel on Mental Health, was previously the Director of the Federal Treatment, Education and Research Endeavor for Narcotic Addiction and Drug Abuse with the National Institutes of Health, and was elected to the Institute of Medicine of the National Academy of Sciences where he was designated a Lifetime National Associate. Dr. Bunney has also served as President of four research organizations: American College of Neuropsychopharmacology, CINP, West Coast College of Biological Psychiatry, and Psychiatric Research Society.
Dr. Bunney received his M.D. from the University of Pennsylvania Medical School and completed his residency in Psychiatry at Yale University School of Medicine. He is the author of more than 390 scientific publications and the editor of seven books.
About CNS Response
CNS Response is a life-sciences data company whose patented system provides treatment guidance to psychiatrists and other physicians for patients with behavioral (mental or addictive) disorders. This technology allows CNS Response to create and provide simple reports ("rEEG(R) Reports") that specifically guide physicians to treatment strategies based on the patient's own physiology.
rEEG(R) utilizes traditional electroencephalography (EEG) in conjunction with a normative database and a proprietary clinical (symptomatic) database to identify the following: (1) medication classes most likely to be needed; and (2) medications within these classes with the most probable treatment potential for each patient. Reports are provided to physicians in a relationship analogous to that of a reference laboratory. Prospective, retrospective and field studies of treatment-resistant patients have reported treatment success of 70% or greater in managed care, outpatient psychiatric and residential substance abuse clinical settings.
In addition to providing analytical support to physicians, CNS Response is also an aid to pharmaceutical developers, who can use rEEG to (1) stratify study populations to improve the success of FDA clinical trials; (2) provide insight on effective therapeutic dosing of investigational drugs; (3) identify additional indications for psychiatric medications; (4) provide insight into effective drug combinations; and (5) discover opportunities for decision analytics and support. In addition to these applications, CNS Response continues to investigate the use of rEEG analysis for development of proprietary pharmaceutical opportunities.
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995
Except for the historical information contained herein, the matters discussed are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These statements involve risks and uncertainties as set forth in the Company's filings with the Securities and Exchange Commission. These risks and uncertainties could cause actual results to differ materially from any forward-looking statements made herein.
SOURCE CNS Response, Inc.
